We investigated the efficacy of irinotecan/cisplatin (IP) versus irinotecan/capecitabine (IX) with or without isosorbide-5-mononitrate (ISMN) in chemo-naïve advanced non-small-cell lung cancer.
introduction Platinum-based chemotherapy has been considered as the standard treatment for patients with advanced non-small-cell lung cancer (NSCLC). However, recent meta-analysis and randomized phase III trials suggest that platinum-based chemotherapy may be challenged by modern third-generation combination regimens. Due to the better tolerability and similar effects on survival, third-generation non-platinum combinations are valid options for patients who have concerns about toxicity [1, 2] . Previously, we investigated gemcitabine plus vinorelbine (GV) chemotherapy with irinotecan plus cisplatin (IP) chemotherapy as first-line therapy and then crossed over at the time of disease progression in patients with advanced NSCLC. While IP showed higher response rates (RRs) compared with GV, there was no significant difference in overall survival (OS). We concluded that either platinum-based chemotherapy followed by non-platinum chemotherapy or non-platinum chemotherapy followed by platinum-based chemotherapy seems to be acceptable for the treatment of advanced NSCLC [3] . We also reported that as non-platinum regimens, such as irinotecan plus capecitabine (IX) and docetaxel plus capecitabine (DX), showed promising antitumor activities for patients with advanced NSCLC [4] [5] [6] [7] .
Given the favorable survival outcome and mild toxicity profiles of IX [4, 5] , we initiated a randomized phase II study of IX versus IP in advanced NSCLC patients. In order to keep balance in providing chemotherapeutic agents used during each patient's disease course, we predefined the second-line therapies, docetaxel plus capecitabine (DX) for IP arm patients and docetaxel plus cisplatin (DP) for IX arm patients after disease progression.
During the study period, Yasuda et al. [8] reported an interesting clinical data showing that nitroglycerine given together with vinorelbine and cisplatin (VP) chemotherapy significantly improved RR and survival compared with the VP chemotherapy alone.
Nitric oxide (NO) is a chemical messenger involved in vasodilatation, neurotransmission, and anti-platelet aggregation. Hypoxia increases drug resistance of tumor cells supposedly by inhibiting endogenous NO production since O 2 is required for cellular production of NO by the enzyme nitric oxide synthase (NOS) [9] . Studies have shown that inhibiting NO production via hypoxic environments or treatment with an NOS antagonist leads to increased tumor cell chemoresistance. On the other hand, replacing NO activity with NO mimetics attenuates the development of chemoresistance [10, 11] . In addition, NO-releasing vasodilators, such as isosorbide-5-mononitrate (ISMN) and isosorbide dinitrate (ISDN), inhibit angiogenesis, tumor growth, and metastasis in an animal tumor model [12] . To evaluate the potential benefits of NOenhancing drugs on the response to chemotherapy and the survival of patients with advanced NSCLC, we amended our study protocol and investigated the effects of ISMN given concurrently with IP and IX in chemo-naïve patients with advanced NSCLC.
patients and methods eligibility Patients (≥18 years of age) with a cytological or histological confirmation of NSCLC, stage-IIIB (with malignant pleural effusion) or stage-IV (AJCC 6 th edition), a performance status (PS) of zero, one, or two on the Eastern
Cooperative Oncology Group (ECOG) scale, and no prior therapy for advanced-stage disease were eligible. The presence of a measurable disease was required. The qualifying laboratory criteria were as follows: leukocytes of ≥4000/μl, platelets of ≥100 000/μl, total serum bilirubin ≤1.0 × the institutional upper limit of normal (ULN), serum transaminases of ≤2.0 × ULN, and serum creatinine levels ≤1.0 × ULN. Patients with brain metastases were included in the study unless they had clinically significant neurological symptoms or signs. Those who had received vasodilators, such as calcium channel blockers, or had ischemic heart disease were excluded. All the patients provided written informed consent, and this study was approved by the institutional review board.
study design and treatment plan
This open-label randomized phase II trial was conducted at a single institution (National Cancer Center, Goyang, Korea). This study was Missed doses of ISMN were not made up, and the treatment cycles were repeated every 3 weeks. Treatment was continued until the point of disease progression, unacceptable toxicity, or the withdrawal of patient consent for a maximum of nine cycles. Since extending chemotherapy beyond a standard number of cycles delays disease progression substantially [13] , we allowed patients to receive up to 9 cycles of chemotherapy as long as patients tolerated.
A predefined second-line therapy was adopted when disease progressed. The patients who had been assigned to IP or IP + ISMN arm received DX [docetaxel (Taxotere®, Dagenham, UK) 30 mg/m 2 IV on days 1 and 8; oral capecitabine 1000 mg/m 2 twice daily on days 1 through 14]. In contrast, the patients who had been assigned to IX or IX + ISMN arm received DP (docetaxel 75 mg/m 2 IV on day 1; cisplatin 60 mg/m 2 IV on day 1). These treatment cycles were repeated every 3 weeks until the point of disease progression or unacceptable toxicity. Appropriate dose interruptions/reductions were implemented in the event of specific toxicities, and these depended on their nature and intensity. The next course of treatment began only when the neutrophil count was >1500/μl, the platelet count was >100 000/μl, or any other treatment-related toxicities were less than or equal to grade 1. Otherwise, treatment was withheld for up to 3 weeks. If adverse events did not improve to a grade of 0 or 1 after 3 weeks, the patients were discontinued from the study. For any patients with hand-foot syndrome of grade 2-3, the capecitabine treatment was withheld until the condition resolved to a grade of ≤1. When this toxicity occurred a second time, treatment was reinitiated with a 25% dose reduction.
patient evaluation
The primary end point was the overall response rate (ORR; the complete response or partial response was identified using RECIST 1.0) [14] . A disease assessment was performed by the investigators every two cycles until the point of progressive disease. Subsequent to the evaluation by the investigator, all measurable and non-measurable lesions were independently assessed by a referee radiologist who was blinded to treatment assignment (HYK). The secondary end points included the progression-free survival (PFS), OS, and safety. Toxicity was assessed throughout treatment and for 30 days following the last treatment. Toxicity was graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (v3.0).
statistical methods
This study employed a 'pick up the winner' design based on the randomized phase II clinical trial approach by Simon et al. [15] , which gave a 92.5% probability of selecting the best treatment if the difference was at least 20% and the smaller response rate was assumed to be 20%. To ensure that at least 140 eligible patients (35 per arm) were enrolled, a minimum of 148 patients were anticipated overall. The patients were stratified according to their gender (male versus female), stage (IIIB versus IV), ECOG PS (0 or 1 versus 2), and histology (squamous cell carcinoma versus non-squamous cell carcinoma). The PFS and OS were evaluated using the Kaplan-Meier method. All the treated patients were included in the efficacy and safety analysis. Although no formal statistical comparison between the treatment arms was anticipated, the binary logistic regression model was used to estimated the odds ratio and their 95% confidence interval (CI) for ORRs. We also used the Cox proportional hazard models to estimate the hazard ratio (HR) and their 95% CI for PFS and OS. Statistical analyses were performed using SPSS and two-sided P-values <0.05 were considered significant.
results patient characteristics
From June 2005 to December 2008, a total of 154 patients with advanced NSCLC were recruited for this study, and 146 patients met the inclusion criteria. Eight patients were excluded at the time of enrollment due to a confirmation of lymphoma (n = 1) or withdrawal of consent from the study (n = 7). The 146 eligible patients were assigned to IP (n = 37), IX (n = 37), IP + ISMN (n = 36), and IX + ISMN (n = 36). Of particular interest, 92% of patients were male and 90% were former or current smokers. Female and never-smokers were much less represented in this study since there was a competing protocol that accrued never-smokers with lung adenocarcinoma [16] . The detailed patients' characteristics are summarized in Table 1 .
treatment
The median number of treatment cycles was six for IP arm, five for IX arm, four for IP + ISMN arm, and four for IX + ISMN arm (Table 2) . Four patients (11%) in IP arm, two (6%) patients in IP + ISMN arm, and two (6%) patients in IX + ISMN arm discontinued treatment after a single cycle of therapy. Disease progression (n = 5) was the most common reason for the early discontinuation of therapy before the second cycle (one patient from IP arm, two from IP + ISMN arm, and two from IX + ISMN arm). Three patients in IP arm did not receive therapy after the first cycle, two patients due to consent withdrawal and one due to toxicity. Figure 3A , online). However, no significant difference in the OS was observed in other comparisons (supplemental Figure 3B and 3C, available at Annals of Oncology online).
second-line treatment
When disease progressed, 84% of the patients in IP arm, 95% in IX arm, 86% in IP + ISMN arm, and 86% in IX + ISMN arm received second-line treatments (Table 1) . Of 73 patients in IP or IP + ISMN arms, 49 patients (67%) received docetaxel and capecitabine (DX) chemotherapy. For the 73 patients given IX or IX + ISMN first, 62 patients (85%) received docetaxel plus cisplatin (DP) chemotherapy after disease progression. Compared with DX chemotherapy, DP chemotherapy showed higher RR (20% versus 42%, P = 0.011) and longer PFS [HR = 1.63 (95% CI 1.11-2.41), P = 0.013, Table 2 ].
toxicity
The frequency of adverse effects in ISMN combination arms was not different from that in the arms without ISMN (Table 3) . Grade-1 or grade-2 headaches were more frequently observed in IP + ISMN (53%; 19 of 36) and IX + ISMN (58%; 21 of 36) arms compared with IP or IX arms (P < 0.001). There were no severe headaches with a grade of ≥3 in the patients from either ISMN arm, and there was no hypotension during ISMN treatment.
Grade 3 or 4 neutropenia was more common in IP (59%; 22 of 37) and IP + ISMN (61%; 22 of 36) arms compared with IX (27%; 10 of 37) or IX + ISMN (17%; 6 of 36) arms.
discussion
This study was originally designed to examine the efficacy of platinum-based doublet chemotherapy (IP) followed by nonplatinum doublet (DX) versus non-platinum doublet followed (IX) by platinum-based doublet (DP) when disease progressed. Although single agent docetaxel, pemetrexed, or epidermal growth factor receptor-tyrosine kinase inhibitors represent the standard second-line treatment for advanced NSCLC, the results observed with these treatments are poor with RR of <10% and PFS of <3 months [17] [18] [19] [20] . Furthermore, many patients still have good PS and can be considered for active treatment. Thus, we used doublet chemotherapy with different action mechanisms and toxicity profiles as second-line therapy to improve the treatment efficacy. Similar to previous reports, IP showed higher RR and longer PFS compared with IX. However, more patients in IX arm, which showed more tolerable toxicity profiles, received preplanned second-line treatment, which resulted in more favorable OS. Thus either treatment sequence seems to be acceptable for the treatment of advanced NSCLC.
Another important issue of this study was to evaluate the efficacy of ISMN when given together with chemotherapy in patients with advanced NSCLC. ISMN is the active metabolite of ISDN and is primarily used for managing chronic stable angina. It has a high bioavailability and a longer half-life than ISDN. Due to its easy administration in a once-daily formulation, ISMN treatment also has greater patient adherence [21] . In addition, it is denitrated by the liver more slowly than glyceryl trinitrate [11] . Moreover, preclinical data has supported the antiangiogenic activity of ISMN [22] . Nevertheless, the addition of ISMN to IP or IX chemotherapy did not improve the RR or survival of the patients in our study. Several factors may have contributed to these negative results. First, NO has a complex function in tumor biology; it can have opposing roles depending on its concentration [23] . Furthermore, high levels of NO lead to p53 phosphorylation and increased apoptosis in some tumor cells, although low levels can promote tumor development and progression [24] . In an animal model where the level of inducible nitric oxide (iNOS) can be regulated, low or high iNOS expression is associated with tumor progression or regression, respectively [23] . Similarly, one retrospective study reported that high NOS expression is associated with a favorable prognosis of NSCLC [25] . NO-donating drugs can cause hypotension when administered systemically, therefore, the amount of NO reaching the tumor mass at the maximum tolerated dose may be insufficient for achieving the desired antitumor effects. Second, the heterogeneous molecular profiles of tumors can influence the sensitivity of their malignant cells to NOmediated cytotoxicity. Cancer cells expressing iNOS and wildtype p53 show reduced tumor growth in mice, whereas those with mutated p53 show accelerated tumor growth and promote angiogenesis [26] . The p53 mutations occur more commonly in current or former smokers than in never-smokers [27] . Interestingly, 90% of patients in our study were former or current smokers. The higher frequency of smokers suggests that most patients in our study might have p53 mutations, which might result in less sensitivity to NO-containing agents. We investigated p53 expression in 76 tumor samples and 44 (58%) patients showed p53 expression. In patients with p53 expression, ISMN-containing regimens led to lower RRs and worse prognosis compared with non-ISMN regimens. However, no significant difference was observed in patients without p53 expression (data not shown). These findings may support the hypothesis that p53 abnormalities in lung cancer cells can affect the sensitivity to NO-containing agents. Finally, the effects of NO can be influenced by reactive oxygen species (ROS), which can shift or attenuate NO-mediated signaling in tumor cells. There is evidence that the induction of apoptosis by NO also requires the production of ROS [28] . While nitroglycerin undergoes mitochondrial biotransformation in a process that is associated with an uncoupling of the respiratory chain and the production of ROS, ISMN, and ISDN are metabolized through an extramitochondrial low-affinity pathway that yields negligible quantities of ROS [29] . This difference in nitrate-induced mitochondrial ROS production may also have contributed to the negative results of our study. Although platinum-based chemotherapy regimens remain as the standard first-line therapy for advanced NSCLC, our study suggests that non-platinum regimen used in this study also rendered equivalent efficacy with more tolerable toxicity profiles when appropriate cisplatin-containing regimen is given in a second-line setting. However, the use of ISMN as an NOdonating agent with platinum-based or non-platinum-based chemotherapy did not seem to improve the treatment efficacy. 
